News
Current report No. 7/2021 – The recommendation of the National Centre for Research and Development to co-fund a project for an inhaled drug candidate for the treatment of inflammatory and fibrotic lung diseases, including COVID-19 complications
February 10, 2021 Date: February 10, 2021, time: 5:42 PM Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – confidential information. Content of the report: Management Board of Celon Pharma S.A. (the “Company”) wishes to announce that on 10 February 2021 it received information that the Company’s application for co-funding ofRead more »
Celon Pharma Announces Successful Completion of Phase 1A Trial of CPL’116, JAK-ROCK Inhibitor.
Celon Pharma S.A. today announced the successful completion of its Phase 1A trial of its JAK/ROCK kinases dual inhibitor, CPL’116. CPL’116 was administered orally in single ascending doses in healthy volunteers in order to assess safety and pharmacokinetic parameters (PK). No adverse events associated with administration of the investigational drug were observed, and the trial metRead more »
Current report No. 6/2021 – Completion of a phase IA clinical trial of a drug based on an innovative JAK/ROCK inhibitor – CPL 409116
February 9, 2021 Date: February 9, 2021, time: 8:56 AM Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – confidential information. In relation to the current report No. 39/2020 of 12 November 2020 on receiving approval for a Phase I clinical trial of a drug based on an innovative JAK/ROCK inhibitorRead more »
Current report No. 6/2021 – Completion of a phase IA clinical trial of a drug based on an innovative JAK/ROCK inhibitor – CPL 409116
Topic: Completion of a phase IA clinical trial of a drug based on an innovative JAK/ROCK inhibitor – CPL 409116 Report content:In relation to the current report No. 39/2020 of 12 November 2020 on receiving approval for a Phase I clinical trial of a drug based on an innovative JAK/ROCK inhibitor – CPL 409116 –Read more »
Current report No. 3/2021 – Obtaining a patent for GPR40 receptor agonists and their use in T2D treatment in the US
Subject: Obtaining a patent for GPR40 receptor agonists and their use in T2D treatment in the US Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – confidential information, time: 4:42 PM Content of the report: Management Board of Celon Pharma S.A. (the “Company”) wishes to announce that on January 18, 2021,Read more »
Current report No. 2/2021 – The National Centre for Research and Development recommended co-funding of the project dedicated to the development of a drug based on GPR40 receptor agonists in the treatment of neuropathic pain
Subject: The National Centre for Research and Development recommended co-funding of the project dedicated to the development of a drug based on GPR40 receptor agonists in the treatment of neuropathic pain Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – confidential information, time: 4:27 PM Content of the report: Management BoardRead more »
Celon Pharma at Top Picks by Trigon Investor Conference
On January 21, 2021, representatives of the Company’s Management Board will take part in the Top Picks by Trigon conference. Celon Pharma was among 21 companies recommended by Trigon DM in 2021.
Celon Pharma Announces Positive Falkieri Phase II Results in Treatment-Resistant Bipolar Depression
Jan 8, 2020—Celon Pharma ($CLN.PL) today announced positive top-line results from a Phase II study of Falkieri (proprietary esketamine dry powder inhalation) in acute phase of treatment-resistant bipolar depression. View the webcast from TC See the presentation from the Meeting. In the trial, Falkieri met the primary endpoint with statistically significant reductions in MADRS total scoreRead more »
Current report No. 1/2021 – Positive results of the phase II clinical trial on Celon Pharma’s DPI esketamine in bipolar treatment-resistant depression [03KET2018]
Date prepared: 01/08/2021, 7:23 PM Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – confidential information. Content of the report: In relation to the current report No. 45/2020 regarding the date for the presentation of results of the phase II clinical trial on esketamine-based DPI drug (Falkieri) in bipolar treatment-resistant depression,Read more »
Celon Pharma at J.P. Morgan Annual Healthcare Conference DIGITAL 11-14 January 2021 .
This year, company taking meetings via the Bio Partnering platform during the week of the JP Morgan Healthcare Conference, but will also take part in meetings with foreign investors. Maciej Wieczorek, CEO of Celon Pharma: We have an intensive week of meetings and presentations ahead of us. This year, we use our presence at JPRead more »
